drugset / Trial / NCT01889966

VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension

NCT01889966

Phase 4 Completed 10 enrolled Kerckhoff Heart Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

Sildenafil is a selective pulmonary vasodilator; in patients with a special kind of pulmonary hypertension it is approved for treatment. The trial seeks to find out, whether the acute response to this treatment (= vasoreactivity testing) given intravenously is effective and allows prediction of therapy success during a following oral treatment.

Timeline

Start
2013-04
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sildenafil Unknown 20 mg Oral